[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345011-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345011-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","new-derivatives-of-4-piperidinylphenyl-linked-thiazoles-as-vegfr2-inhibitors-with-potential-cytotoxicity-against-renal-cancer","New Derivatives of 4-Piperidinylphenyl-Linked Thiazoles as VEGFR2 Inhibitors with Potential Cytotoxicity Against Renal Cancer","","A novel series of 4-piperidinylphenyl-linked thiazoles was synthesized and evaluated as VEGFR2 inhibitors with potential cytotoxic activity against renal cancer. Most target compounds inhibited VEGFR2 with sub-micromolar IC50 values, with compounds 7c, 9b, and 9c showing the strongest potency and outperforming sunitinib. These compounds also suppressed A498 renal cancer cell growth, induced apoptosis, and produced cell-cycle arrest for compound 7c. Molecular docking supported a proper binding orientation of 7c in the VEGFR2 active site, and improved safety against non-cancerous cells was suggested relative to sunitinib.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/new-derivatives-of-4-piperidinylphenyl-linked-thiazoles-as-vegfr2-inhibitors-with-potential-cytotoxicity-against-renal-cancer/345011/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/new-derivatives-of-4-piperidinylphenyl-linked-thiazoles-as-vegfr2-inhibitors-with-potential-cytotoxicity-against-renal-cancer/345011.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What VEGFR2-targeting compounds were synthesized and tested in the study?","Question",{"text":63,"@type":64},"The study synthesized a novel series of 4-piperidinylphenyl-linked thiazoles and evaluated them as VEGFR2 inhibitors for cytotoxic activity against renal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which compounds showed the strongest VEGFR2 inhibition and how did they compare with sunitinib?",{"text":68,"@type":64},"Compounds 7c, 9b, and 9c were the most potent, with VEGFR2 inhibition values superior to sunitinib.",{"name":70,"@type":61,"acceptedAnswer":71},"How did compound 7c affect renal cancer cells and what did docking suggest?",{"text":72,"@type":64},"Treatment of A498 renal cancer cells with compound 7c led to apparent cell-cycle arrest and significant apoptosis induction. Docking indicated proper orientation of 7c in the VEGFR2 active site.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345011,1790173479,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Article  \nNew Derivatives of 4-Piperidinylphenyl-Linked Thiazoles as VEGFR2 Inhibitors with Potential Cytotoxicity Against Renal Cancer  \nHuda K. Mahmoud 1, Thoraya A. Farghaly 1,2,*, Hossa F. Alshareef 2, Amani M. R. Alsaedi 3, Afaf Y. Khormi 4, Hanan Gaber Abdulwahab 5, Alaa M. Abu Alnjaa 6 and Shadia M. Hussein 7  \n1 Department of Chemistry, Faculty of Science, University of Cairo, Giza 12613, Egypt  \n2 Department of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia  \n3 Department of Chemistry, Collage of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia  \n4 Department of Chemistry, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia  \n5 Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754, Egypt  \n6 Department of Chemistry, Jamoum University College, Umm Al-Qura University, Makkah 21955, Saudi Arabia  \n7 Department of Chemical Pathology, Cairo University Hospital, University of Cairo, Giza 12613, Egypt  \n* Correspondence: [thoraya-f@cu.edu.eg or](thoraya-f@cu.edu.eg or) [thoraya-f@hotmail.com](thoraya-f@hotmail.com)  \nAbstract  \nHerein, a novel series of 4-piperidinylphenyl-linked thiazoles was synthesized as VEGFR2 inhibitors with potential cytotoxic activity against renal cancer. Most of the target compounds inhibited VEGFR2 enzyme at sub-micromolar IC50 values. Compounds 7c (IC50 = 0.073 ± 0.002 µM), 9b (IC 50 = 0.049 ± 0.002 µM), and 9c (IC50 = 0.093 ± 0.003 µM) were the most potent, showing VEGFR2 inhibition superior to that of sunitinib (IC50 = 0.118 ± 0.003 µM) . Furthermore, compounds 7c, 9b, and 9c effectively inhibited the growth of A498 renal cancer cells, with compound 7c being the most potent showing a one-digit IC 50 value of 7.866 ± 0.27 µM. In addition, compound 7c revealed a potentially improved safety profile against non-cancerous normal cells, relative to sunitinib. The treatment of A498 renal cancer cells with compound 7c led to an apparent cell cycle arrest and a significant induction of apoptosis. A docking study was also conducted and revealed a proper orientation of compound 7c into the active site of VEGFR2 .  \nAcademic Editors: Tamal Kanti Das, Arun Raja and Balraj Gopula  \nReceived: 29 January 2026  \nRevised: 25 February 2026  \nAccepted: 27 February 2026  \nPublished: 28 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKeywords: thiazole; VEGFR2 inhibitors; cytotoxic; renal cancer; docking study  \n1. Introduction  \nVascular endothelial growth factor-2 (VEGFR2), a transmembrane tyrosine kinase receptor, has a crucial role in facilitating angiogenesis [1,2] . Angiogenesis is a multifaceted process that entails the development of new vascular structures from established blood vessels. Angiogenesis is a crucial biological process that supplies nutrition and oxygen to growing cells, facilitating tumor growth, development, and invasion. VEGFR2 is evidently overexpressed and/or hyperactivated throughout the course of cancer progression. Therefore, targeting VEGFR2 signaling pathway is well-established as an important approach for targeted antiangiogenic therapy, and several VEGFR2 inhibitors have been clinically approved as anticancer agents [3–8] .  \nMoreover, kidney cancer ranks among the most prevalent malignancies in both men and women, exhibiting a steadily increasing global incidence along with significant morbidity and fatality rates worldwide [9] . Being a highly vascularized solid tumor, angiogenesis process is crucial in the progression and dissemination of renal cancer. Renal cell carcinoma has been molecularly linked to VEGF signaling pathway [2,5] . Accordingly, significant efforts have been undertaken to produce anti-angiogenic medications to treat renal cancer, speci","cbCaitREyy5CViz2","https://ap.wps.com/l/cbCaitREyy5CViz2","pdf",1883161,18,"English","# 1. Introduction\n## VEGFR2 and targeted antiangiogenic therapy\n## Renal cancer prevalence and VEGF signaling\n## Clinically approved VEGFR2 inhibitors and resistance challenge\n## Thiazole heterocycles in medicinal chemistry\n## Piperidine moiety in tyrosine kinase inhibitors\n## Molecular basis of VEGFR2–sunitinib interaction","[{\"question\":\"What VEGFR2-targeting compounds were synthesized and tested in the study?\",\"answer\":\"The study synthesized a novel series of 4-piperidinylphenyl-linked thiazoles and evaluated them as VEGFR2 inhibitors for cytotoxic activity against renal cancer.\"},{\"question\":\"Which compounds showed the strongest VEGFR2 inhibition and how did they compare with sunitinib?\",\"answer\":\"Compounds 7c, 9b, and 9c were the most potent, with VEGFR2 inhibition values superior to sunitinib.\"},{\"question\":\"How did compound 7c affect renal cancer cells and what did docking suggest?\",\"answer\":\"Treatment of A498 renal cancer cells with compound 7c led to apparent cell-cycle arrest and significant apoptosis induction. Docking indicated proper orientation of 7c in the VEGFR2 active site.\"}]","New Derivatives of 4-Piperidinylphenyl-Linked Thiazoles as VEGFR2 Inhibitors with Potential Cytotoxicity Against Renal Cancer | PDF",1790056205,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7ffcf265cf4d4643dc7603e54179cb3.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe753ff7226ee4a9826e1d4433ce66f8.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/857a629e74e4d6af8d0f73fe33125150.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85803ea50a2c06e69c2faaaafe500d76.webp",980,1385]